RetinAI

Bern, Switzerland  All Switzerland companies → — Founded 2017
Imaging AI Specialist Specialty-Focused AI
Ophthalmology
Ophthalmology AI
Acquired by EssilorLuxottica — Approximately $19.66M (prior to acquisition)
Website Claim this company

Products

RetinAI Discovery
RetinAI
Ophthalmology AI
RetinAI Discovery is an FDA-cleared and CE-Marked medical image and data management platform with certified AI models for aggregating data and extracting automatic insights on patient diseases and outcomes in ophthalmology, including diabetic retinopathy, diabetic macular edema, glaucoma, and geographic atrophy.
Contact for pricing

See all 1 product →

About RetinAI

RetinAI, now operating under the umbrella of EssilorLuxottica following its acquisition in October 2025, is a leading healthcare AI company specializing in advanced software solutions for ophthalmology. The company’s flagship platform, RetinAI Discovery®, leverages machine learning and computer vision to collect, organize, and analyze large-scale retinal images and biomarker datasets. This platform is designed to streamline clinical, research, and pharmaceutical workflows, providing healthcare professionals with actionable, AI-driven insights to enhance patient care and accelerate R&D.

For physicians, RetinAI’s technology supports more accurate and timely decisions in managing various eye diseases, including age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy. The platform is FDA-cleared 510(k) and CE-marked, indicating its compliance with regulatory standards for clinical use. Beyond clinical applications, RetinAI partners with pharmaceutical companies and research organizations to utilize real-world evidence, thereby accelerating clinical studies and drug development processes.

Focus Areas

Ophthalmology Neurodegenerative Conditions Vascular Diseases Rare Diseases & 'Omics' Clinical Trials Multicenter Collaborations Real World Data Data Management AI Analysis AI Automation Age-related Macular Degeneration (AMD) Diabetic Retinopathy (DR) Diabetic Macular Edema (DME) Glaucoma Geographic Atrophy (GA) Retinal Vein Occlusion (RVO)

Business Intelligence

Key InvestorsSanoptis, THINC Ventures (Topcon Healthcare, Inc.), Zürcher Kantonalbank (ZKB), b2venture (formerly btov Partners), Matterwave Ventures, Verve Ventures, Investiere, private investors
PartnershipsFVS, MAXO, Stephen J. Ryan Initiative for Macular Research (RIMR) AMD Consortium, Retina Consultants of America, Boehringer Ingelheim, Eyestem Research, Novartis, J&J, EssilorLuxottica (commercial agreement for distribution)
AcquisitionsAcquired by EssilorLuxottica (October 2025)
TechnologyRetinAI Discovery® platform (medical image & data management platform), AI models for automatic analysis, cloud-based, web browser access, multi-modal imaging compatibility (OCT, Fundus, DICOM), generative AI tools, Discovery CONNECT (for automated imaging data sync)
FDA Clearances1 cleared products (estimated)

Products by RetinAI

1 product in the directory

RetinAI Discovery
RetinAI
Ophthalmology AI
RetinAI Discovery is an FDA-cleared and CE-Marked medical image and data management platform with certified AI models for aggregating data and extracting automatic insights on patient diseases and outcomes in ophthalmology, including diabetic retinopathy, diabetic macular edema, glaucoma, and geographic atrophy.
Contact for pricing

Reviews & Opinions

No web reviews on file yet for RetinAI. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about RetinAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for RetinAI →

View all on YouTube

Press & Coverage

RetinAI
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions
EssilorLuxottica acquired Ikerian AG, operating as RetinAI, a health technology company specializing in AI and data management in eyecare. This acquisition aims to enhance EssilorLuxottica's med-tech journey by integrating RetinAI's advanced software for streamlined clinical, research, and pharmaceutical workflows, and to deliver actionable AI-driven insights for healthcare professionals and improved patient care.
2025-10
RetinAI
Ikerian Announces Series B Funding First close of USD 8M Led by Sanoptis with Commercial Agreement to Expand RetinAI Discovery in Europe
Ikerian AG, parent company of RetinAI, secured $8 million in the first close of its Series B funding round, led by Sanoptis. This funding will support the expansion of the RetinAI Discovery platform across Europe and further develop its AI technology for large-scale data management and improved healthcare data workflows.
2024-10
RetinAI
RetinAI Announces Strategic Partnership with Eyestem to Innovate Geographic Atrophy Clinical Research Using State-of-the-Art AI Technology
RetinAI partnered with Eyestem Research to advance Geographic Atrophy (GA) clinical research using RetinAI's Discoveryu00ae platform and AI tools. This collaboration aims to revolutionize GA treatment approaches by integrating AI-driven analytics with Eyestem's cell therapy, Eyecyte-RPEu2122.
2023-10
RetinAI
Ikerian (parent company of RetinAI U.S. Inc.) receives EU-MDR Certificate for four devices, its Ophthalmology Data Platform and AI models
Ikerian AG announced the registration of four devices, including RetinAI Discoveryu00ae and its AI-based models, as Class IIa medical devices under the European Union Medical Device Regulation (EU-MDR). This certification highlights RetinAI's commitment to high-quality standards and compliance with robust regulatory frameworks for healthcare technology.
2024-06
RetinAI
RetinAI Discoveryu00ae platform and AI tools launched to improve decision workflows, referrals and patient management in Clinics for Ophthalmologists and Optometrists
Ikerian AG and RetinAI Inc. US launched RetinAI Discoveryu00ae for Clinics, offering two versions for ophthalmologists and optometrists. This platform and its AI models are designed to accelerate and enhance clinical decision workflows, teleophthalmology management, and patient management.
2024-02
Greater Geneva Bern area
Ikerian, parent company of RetinAI, secures USD 6.18 million for AI-driven medical advancements
Ikerian AG, with its subsidiary RetinAI, completed a $6.18 million Series A extension financing round to advance the development and commercial rollout of innovative medical technologies. The funding, led by Topcon Healthcare, Inc., will support RetinAI's Discovery platform and its expansion into new therapeutic areas beyond ophthalmology.
2024-05
RetinAI
RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions
RetinAI and OptymEdge announced a collaboration to accelerate ophthalmic drug development by integrating RetinAI Discoveryu00ae and AI capabilities with OptymEdge's Reading center. This initiative aims to optimize clinical trial workflows and expedite time-to-market for new therapies.
2024-01
RetinAI
RetinAI receives FDA Clearance for Discovery, our medical image & data management platform for Ophthalmology
RetinAI Medical AG announced U.S. Food and Drug Administration (FDA) 510(k) clearance of RetinAI Discoveryu00ae, its image and data management platform for ophthalmology. The platform is designed to organize and analyze ophthalmic medical images and facilitate collaborative analysis of clinical cases.
2022-05

Frequently Asked Questions

RetinAI's primary product is the Discovery platform, offered in versions like Discovery for Clinics, Discovery for Clinical Studies, and Discovery UNITY, alongside Discovery CONNECT for automated data syncing. These solutions provide AI-driven data management and analysis for various ophthalmological conditions such as AMD, DR, DME, Glaucoma, GA, and RVO, with ongoing expansion into neurodegenerative, vascular, and rare diseases.
RetinAI's Discovery platform holds FDA 510(k) clearance and CE-MDR certification, demonstrating its adherence to medical device regulations in the US and Europe. The company also complies with ISO 13485 for quality management, HIPAA for patient privacy, GDPR for data protection in the EU, and 21 CFR Part 11 for electronic records and signatures in clinical studies.
RetinAI's Discovery platform, particularly Discovery for Clinical Studies and Discovery UNITY, offers a cloud-based environment for multi-modal data collection and management, accelerating clinical trials through AI-driven endpoint analysis. The company actively engages in multicenter collaborations and partnerships, such as with Retina Consultants of America, to build extensive real-world evidence (RWE) databases, providing insights into treatment effectiveness and patient outcomes.
RetinAI's AI analysis and automation tools are designed to address a range of vision-threatening ophthalmological conditions, including Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Glaucoma, Geographic Atrophy (GA), and Retinal Vein Occlusion (RVO). Their AI models provide insights through biomarker quantification, retinal layer segmentation, fluid analysis, and disease progression prediction.
RetinAI has forged strategic partnerships with leading pharmaceutical companies like Novartis and Boehringer Ingelheim to advance novel treatments and AI identification of conditions like Geographic Atrophy. Collaborations with Retina Consultants of America aim to build comprehensive US-based real-world evidence databases, while partnerships with Heidelberg Engineering and Sanoptis expand the integration of RetinAI's AI tools with imaging devices and enhance market distribution across Europe.
RetinAI, operating under its parent company Ikerian AG, has demonstrated strong company stability with successful Series A extension and Series B funding rounds, totaling over $11 million in equity finance. These funds support continued development and commercial rollout of the Discovery platform in ophthalmology and optometry, alongside strategic expansion into new therapeutic areas such as neurodegenerative disorders, vascular conditions, and rare diseases.
RetinAI's Disease Evaluation Apps are offered on a usage-based pricing model, often through subscriptions that provide access to various apps with credits. For their comprehensive Discovery platform and tailored solutions for clinical studies or enterprise use, specific pricing typically requires a custom quote. Healthcare providers can expect collaborative support, including project management and expert teams, to help integrate and leverage the platform's AI-driven insights for enhanced workflows and data analysis.

Investors

Who's funded RetinAI.

Nebular
VC T3
New York, United States
$250k-$1M
Nebular, also referenced as Nebular Venture Capital, is a venture firm with a website, LinkedIn, and Crunchbase footprint consistent with a small…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services

Related Companies

Visiopharm
Hørsholm, Denmark (Medicon Valley)

Visiopharm is a leading provider of AI-driven precision pathology software, catering to both research and diagnostic applications. For physicians, Visiopharm offers advanced tools that transform pathology through image analysis, aiming to enhance precision and productivity in pathology labs. The company has developed nine diagnostic algorithms cleared under IVDR for EU and UK customers, which provide […]
TSI (Transworld Systems Inc.)
Andover, MA

TSI (Transworld Systems Inc.) is a long-standing company primarily known for its debt collection and business process outsourcing services. While they serve various industries, including healthcare, their core offering is focused on accounts receivable management and collections rather than healthcare-specific AI development. They provide solutions to help healthcare providers manage patient accounts, improve cash flow, […]
TrialX
New York, NY, United States [2, 5]

TrialX is a healthcare AI company specializing in clinical research and space health informatics. The company develops platforms designed to connect patients with clinical trials and facilitate research data collection. Their offerings include an enterprise patient recruitment platform (iConnect) that provides a clinical trials finder (Dory), study website builders, pre-screeners, referral tracking, and volunteer registries. […]
Thinkitive
Pune, India (with offices in Nashik, India, and New Jersey, USA)

Thinkitive is a global IT services and solutions company that specializes in digital transformation, enterprise application services, outsourced product development, and a testing center of excellence. For physicians, Thinkitive offers a range of AI-driven healthcare solutions designed to streamline clinical and administrative workflows, enhance patient care, and improve operational efficiency. Their services include custom healthcare […]
Taction Software
Chicago, Illinois, USA, with offices in Cheyenne, WY, Austin, TX, Sacramento, CA, and Tomball, Texas. They also have an office in Noida, India.

Taction Software is a U.S.-based healthcare IT and custom software development company specializing in HIPAA-compliant solutions. They build AI-powered applications for healthcare, ranging from rapid clinical AI prototypes to production-grade systems with EHR integration, ambient documentation, and predictive analytics. The company focuses on transforming healthcare delivery through secure, compliant, and innovative software solutions that aim […]
Superwise
Nashville, United States (acquired by Blattner Tech) / Tel Aviv, Israel (original Superwise.ai)

SUPERWISE offers an enterprise AI governance and operations platform designed to help organizations, including those in healthcare, deploy and manage autonomous AI systems with oversight and control. The platform addresses governance, compliance, and operational challenges associated with AI and machine learning deployments. It features real-time guardrails for AI systems, model observability capabilities, and compliance automation, […]
Suggest an Edit →
AI Tool Finder
AI-powered search. Results may not be comprehensive.